18 July 2023
18 July 2023
Increased patent publications over a two-week period to help decimate challenges associated with the treatment of rare diseases.
The highly anticipated trial readout on Eli Lilly’s donanemab comes after a failed attempt to gain accelerated approval.
Statistically significant improvements were observed in fatigue, pain, and symptoms of autonomic dysfunction.
Patients received five-day courses of a subcutaneous dosage of ld IL-2 for four monthly cycles.
Alnylam’s pipeline drug ALN-APP has shown positive results for patients with early-onset Alzheimer’s disease and is well tolerated.
The company is enrolling subjects to initiate its Phase III DRAGON study of Tinlarebant in adolescent STGD1 patients.
The company anticipates initiating the Phase Ib stage after completion of the first cohort.
Topline results from the study are anticipated in the third quarter of next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
